CAR-T

ASCO: BMS pitches Breyanzi as the first CAR-T for CLL. But will a single-arm trial persuade the FDA?
ASCO: BMS pitches Breyanzi as the first CAR-T for CLL. But will a single-arm trial persuade the FDA?
Fierce Pharma
ASCO 2023
Bristol Myers Squibb
Breyanzi
CAR-T
CLL
SLL
clinical trials
Flag link:
J&J Makes $245M Play to Develop Next-Gen CAR-T Therapies
J&J Makes $245M Play to Develop Next-Gen CAR-T Therapies
BioSpace
JNJ
Janssen
Cellular Biomedicine
CAR-T
diffuse large B-cell lymphoma
Flag link:
J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows
J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows
Fierce Pharma
CAR-T
Bristol Myers Squibb
JNJ
Legend Biotech
AACR
Multiple Myeloma
Carvykti
Abecma
Flag link:
Caribou gets FDA fast track for allogeneic CAR-T
Caribou gets FDA fast track for allogeneic CAR-T
Biopharma Reporter
Caribou Biosciences
FDA
Multiple Myeloma
CAR-T
CB-011
Flag link:
Gilead’s Yescarta extends survival in lymphoma study
Gilead’s Yescarta extends survival in lymphoma study
BioPharma Dive
Gilead Sciences
Yescarta
CAR-T
lymphoma
large B-cell lymphoma
Flag link:
Johnson & Johnson shelves Carvykti's UK launch amid manufacturing shortfalls
Johnson & Johnson shelves Carvykti's UK launch amid manufacturing shortfalls
Fierce Pharma
JNJ
Legend Biotech
CAR-T
Carvykti
Flag link:
Cancer drug startup Cargo raises $200M to solve CAR-T relapse
Cancer drug startup Cargo raises $200M to solve CAR-T relapse
BioPharma Dive
Cargo Therapeutics
lymphoma
CAR-T
Flag link:
OCI-led CAR-T leukemia therapy receives €2.5m from EIC
OCI-led CAR-T leukemia therapy receives €2.5m from EIC
Pharmaphorum
OneChain
Europe
CAR-T
leukemia
Flag link:
Bristol Myers details landmark Abecma multiple myeloma data that ASH turned down
Bristol Myers details landmark Abecma multiple myeloma data that ASH turned down
Fierce Pharma
Bristol Myers Squibb
Abecma
CAR-T
Multiple Myeloma
Flag link:
Bristol Myers claims win with CAR-T therapy Breyanzi in leukemia
Bristol Myers claims win with CAR-T therapy Breyanzi in leukemia
Endpoints
Bristol Myers Squibb
CAR-T
Breyanzi
CLL
cell therapy
Flag link:
After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE
After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE
Fierce Pharma
Gilead Sciences
CAR-T
Yescarta
UK
NICE
Kite Pharma
Novartis
blood cancer
Flag link:
Kite swoops in to buy Carl June-founded Tmunity, gaining key to Penn's CAR-T research apparatus
Kite swoops in to buy Carl June-founded Tmunity, gaining key to Penn's CAR-T research apparatus
Fierce Biotech
Kite Pharma
Gilead Sciences
M&A
CAR-T
Tmunity
Carl June
Flag link:
ASH: Novartis stays the course with cell therapy bet as competitors line up 'off-the-shelf' options
ASH: Novartis stays the course with cell therapy bet as competitors line up 'off-the-shelf' options
Fierce Biotech
Novartis
ASH 2022
CAR-T
T-Charge
Flag link:
ASH: In next BCMA myeloma race, Gracell dazzles with 100% response rate as Pfizer, BMS place their bets
ASH: In next BCMA myeloma race, Gracell dazzles with 100% response rate as Pfizer, BMS place their bets
Fierce Biotech
ASH 2022
Gracell
CAR-T
Multiple Myeloma
Bristol Myers Squibb
Pfizer
Flag link:
ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead
ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead
Fierce Pharma
Bristol Myers Squibb
Breyanzi
B-cell lymphoma
CAR-T
ASH 2022
Flag link:
With Neogene buy and a CAR-T in the clinic, AstraZeneca builds up cell therapy 'library'
With Neogene buy and a CAR-T in the clinic, AstraZeneca builds up cell therapy 'library'
Fierce Biotech
AstraZeneca
Neogene Therapeutics
CAR-T
cell therapy
cell library
Flag link:
Beam jumps back into off-the-shelf CAR-T race after FDA lifts clinical hold
Beam jumps back into off-the-shelf CAR-T race after FDA lifts clinical hold
Fierce Biotech
Beam Therapeutics
FDA
CAR-T
clinical trials
BEAM-201
Flag link:
Sana lays off 15%, trims pipeline to keep funding flowing to off-the-shelf CAR-Ts
Sana lays off 15%, trims pipeline to keep funding flowing to off-the-shelf CAR-Ts
Fierce Biotech
Sana Biotechnology
layoffs
CAR-T
cell therapy
Flag link:
Pulling back the curtain on AstraZeneca’s CAR-T work
Pulling back the curtain on AstraZeneca’s CAR-T work
EP Vantage
AstraZeneca
CAR-T
AZD0754
cell theray
Flag link:
Gilead dodges Supreme Court review—and a $1.2B fine—in CAR-T patent feud with Bristol Myers
Gilead dodges Supreme Court review—and a $1.2B fine—in CAR-T patent feud with Bristol Myers
Fierce Pharma
Gilead Sciences
Kite Pharma
Bristol Myers Squibb
cell therapy
legal
CAR-T
Yescarta
Flag link:

Pages